Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BOLT · NASDAQ · Pharmaceutical Preparations
Bolt Biotherapeutics (BOLT) · oqro.io/stocks/BOLT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$6.08+0.17 (+2.88%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
132 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Insider buying
Bought outside the usual windowTraded Nov 9 · filed 1 day later
Since the trade −5.4% · S&P 500 +0.2% · to Nov 13
A major shareholder of Bolt Biotherapeutics paid $319K out of pocket for Bolt Biotherapeutics shares. Shares held went up 12% with this purchase.
William P. Quinn (President, CEO and CFO) sold ~$30K of Bolt Biotherapeutics
Automatic saleWilliam P. Quinn (President, CEO and CFO) sold ~$22K of Bolt Biotherapeutics
Automatic saleWilliam P. Quinn (President, CEO and CFO) sold ~$7.1K of Bolt Biotherapeutics
Automatic saleGrant Yonehiro (Chief Operating Officer) sold ~$22K of Bolt Biotherapeutics
Automatic saleGrant Yonehiro (Chief Operating Officer) sold ~$16K of Bolt Biotherapeutics
Automatic saleSarah Nemec (Senior VP, Finance and PAO) sold ~$13K of Bolt Biotherapeutics
Automatic saleSarah Nemec (Senior VP, Finance and PAO) sold ~$9.7K of Bolt Biotherapeutics
Automatic saleSarah Nemec (Senior VP, Finance and PAO) sold ~$3.2K of Bolt Biotherapeutics
Automatic saleGrant Yonehiro (Chief Operating Officer) sold ~$5.3K of Bolt Biotherapeutics
Automatic sale1 open-market purchase and 9 open-market sales by insiders of BOLT between Feb 10, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 12, 2026. The data provider lists the next release for Mar 10, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 12, 2026 | 1 purchase | None | None |
| Aug 11, 2026 | None | None | None |
| May 12, 2026 | None | None | None |
| Mar 12, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
